Co-Diagnostics Inc
Co-Diagnostics Inc (CODX) is a microcap molecular diagnostics company that develops and licences PCR-based tests using its proprietary CoPrimer technology. The business focuses on infectious disease diagnostics — most notably assays for respiratory viruses — and generates revenue through test kit sales, licensing agreements and contract research. With a market capitalisation around $16 million, CODX is small and can be volatile; earnings and contract timing can cause rapid share-price moves. Key investor considerations include regulatory approvals, laboratory adoption, supply-chain capacity and cash runway, since smaller diagnostics firms often face funding and commercialisation hurdles. Potential catalysts are new contracts, wider regulatory clearance and partnerships, while risks include competitive pressure, reimbursement dynamics and dilution from fundraising. This is educational information only and not personalised advice; investors should assess their own risk tolerance and perform further research.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Co-Diagnostics' stock, expecting its value to rise significantly.
Financial Health
Co-Diagnostics is generating modest revenue and cash flow, but faces challenges with profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CODX
Liquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Small‑cap volatility
CODX’s microcap status can lead to big price swings on news or results; this creates opportunity but also higher risk and lower liquidity.
Diagnostic tech focus
Proprietary CoPrimer PCR assays are central to its offering; tech adoption and validation are key commercial levers, though outcomes are uncertain.
Partnerships and approvals
New regulatory clearances or distribution deals can drive growth, but regulatory hurdles and competitive bids may delay impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
